{
    "clinical_study": {
        "@rank": "8090", 
        "arm_group": [
            {
                "arm_group_label": "Azopt 1% ophthalmic suspension", 
                "arm_group_type": "Active Comparator", 
                "description": "Ophthalmic suspension"
            }, 
            {
                "arm_group_label": "Brinzolamide 1% ophthalmic suspension", 
                "arm_group_type": "Experimental", 
                "description": "ophthalmic suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this prospective study is to demonstrate the therapeutic equivalence of\n      topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic\n      suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH."
        }, 
        "brief_title": "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma,", 
            "Open Angle or Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and females 18 years of age or older,\n\n          -  diagnosed with primary open-angle glaucoma or ocular hypertension.\n\n        Exclusion Criteria:\n\n          -  Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal\n             tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle\n             glaucoma,\n\n          -  ocular hypertension."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722604", 
            "org_study_id": "CD-11-265"
        }, 
        "intervention": [
            {
                "arm_group_label": "Brinzolamide 1% ophthalmic suspension", 
                "description": "brinzolamide 1% ophthalmic suspension", 
                "intervention_name": "brinzolamide 1% ophthalmic suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Azopt 1% ophthalmic suspension", 
                "description": "Azopt 1%, RLD", 
                "intervention_name": "Azopt 1%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brinzolamide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Various"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment.", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Reduction in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "InnoPharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InnoPharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}